Pharma speaks loud and clear on need for 101 changes, but consensus for reform remains elusive
US life sciences leadership is at stake, industry tells USPTO, but comments on eligibility study show deep divisions remain
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.